Biliary tract cancers therapeutic studies summarized by Erman Akkus at AACR
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“Biliary tract cancers- therapeutic studies at AACR24.
- 2098 / 22 – A novel GCN2 kinase activator, NXP800, demonstrates therapeutic efficacy in preclinical cell lines and PDX models.
- 2127 / 18 –Surufatinib, an oral tyrosine kinase inhibitor, enhances radiosensitivity preclinically.
- CT133 / 12 – A phase 1b study of anti-TIM3 (S095018/Sym023) in combination with anti-PD1 (Sym021) exhibited antitumor activity in patients with advanced/metastatic recurrent biliary tract cancer who had not received prior treatment with PD-1/-L1 inhibitors. ( 2 PR (5.7%), 11 SD (31.4%), 18 PD (51.4%) and 4 not evaluable. Median PFS and OS were 1.9 m and 13.4 months).
- 4536 / 12 -MRTX1719 (targets the MTAP) plus Olaparib shows synergy in cell lines.
- 4604 / 2 – Imipridones ONC201 and ONC212 exhibit anti-tumor activity in biliary tract cancers and synergy when combined with Trametinib and Olaparib in vitro.
- 5711 / 11 – Fadraciclib (CDK2/9 dual inhibitor) shows efficacy alone or in combination with Olaparib (PARP inhibitor) or JQ1 (BRD4 inhibitor), preclinically.
- 5753 / 21 – Aptamer guided, nanovesicle mediated transcriptome targeting is a promising therapeutic strategy in preclinical CCA models that may potentiate chemotherapy response.
- 933 / 1 – Single-cell inference and validation of heterogeneous drug sensitivity reveals Dacinostat may be novel therapeutic candidate.
- 4325 / 10 – CX-4945 (Silmitasertib) (a CK2 inhibitor) induces cell death in KRAS mutant cholangiocarcinoma cell lines.
- humanized monoclonal antibodies targeting claudin-1 shows efficacy preclinically.
- 7271 / 8 – Proteasome inhibitor FHND6091 shows efficacy in PTEN-deficient cholangiocarcinoma, preclinically.
- 6525 / 10 -Targeting sulfatase-2 modulates the immune response, preclinically.”
Source: Erman Akkus/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023